Corcept Therapeutics (HAM:HTD) Moat Score: 4/10 (As of Jun. 27, 2026)


HAM:HTD Corcept Therapeutics Inc HAM:HTD
82 GF Score
Price €73.14
GF Value €51.66
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Moat Score?

Corcept Therapeutics HAM:HTD +3.60% 82 Moat Score is 4 as of Jun. 27, 2026. GuruFocus rates HAM:HTD with a GF Score™ of 82/100 and a GF Value™ of €51.66. The stock has 8 warning signs investors should review. Among 1,404 Biotechnology companies, Corcept Therapeutics ranks better than 88.82% on this metric.

Corcept Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Corcept Therapeutics has Narrow Moat: Corcept Therapeutics Inc has valuable intellectual property and patents in the pharmaceutical sector. However, its market share and brand strength are not robust enough to warrant a stronger moat classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Corcept Therapeutics might have Narrow Moat - Discernible but modest moat.

Corcept Therapeutics  (HAM:HTD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Corcept Therapeutics Moat Score Related Terms

HAM:HTD vs PCVX, IBRX, HALO: Moat Score Comparison

For the Biotechnology subindustry, Corcept Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corcept Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Moat Score falls into.


HAM:HTD
82GF Score
Corcept Therapeutics Inc HAM:HTD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Corcept Therapeutics (HAM:HTD) has a Moat Score of 4 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Corcept Therapeutics ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Corcept Therapeutics' Moat Score too high?
Corcept Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Corcept Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Moat Score compare to PCVX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #157 out of 1404 companies for Moat Score. This places Corcept Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Corcept Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Moat Score of 4. The stock's GF Value™ is €51.66, compared to a current price of €73.14 — trading 41.6% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Moat Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €73.14 is trading 41.6% above its estimated GF Value™ of €51.66.

Key valuation signals for HAM:HTD:

  • Moat Score: 4
  • GF Value™: €51.66 vs. price of €73.14 (41.6% above fair value)
  • GF Score™: 82/100 with 8 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1404)

No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score

Get the complete analysis for HAM:HTD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.14
Price
€51.66
GF Value